Data / Drug companies / Par Health USA, LLC
Par Health USA, LLC: 62 products in the FDA NDC directory, labeler code 42023
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Par Health USA, LLC (labeler code 42023) lists 62 products in the FDA National Drug Code Directory, covering 31 finished drugs by generic name. By type: 62 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on July 28, 2026.
The request: Watch Par Health USA, LLC (FDA labeler code 42023): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 42023
- Products in commercial distribution
- 62
- Packages
- 66
- Finished drugs by generic name
- 31
- Prescription products
- 62
- Over the counter products
- 0
- Controlled substance products
- Schedule III 4, Schedule IV 1
- Flagged as original packager
- 59 of 59 products that carry the flag
- Started marketing in the last 12 months
- 3
- Products with a marketing end date set
- 1
- Earliest marketing start
- October 1, 2007
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 40 | 64.5% |
| Generic drugs (ANDA) | 22 | 35.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 62 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Vasopressin | 5 | 15 |
| Epinephrine in sodium chloride | 5 | 1 |
| Oxytocin | 4 | 6 |
| Epinephrine | 4 | 32 |
| Ephedrine sulfate | 4 | 26 |
| Levothyroxine sodium anhydrous | 3 | 6 |
| Ketamine hydrochloride | 3 | 11 |
| Dexmedetomidine hydrochloride | 3 | 21 |
| Estradiol valerate | 2 | 4 |
| Sugammadex sodium | 2 | 5 |
| Dantrolene sodium | 2 | 14 |
| Fluphenazine decanoate | 2 | 9 |
| Ertapenem sodium | 2 | 11 |
| Neostigmine methylsulfate | 2 | 24 |
| Phenylephrine hydrochloride | 2 | 77 |
| Argatroban | 2 | 12 |
| Colistimethate | 1 | 1 |
| Ethacrynate sodium | 1 | 2 |
| Naloxone hydrochloride | 1 | 40 |
| Methohexital sodium | 1 | 3 |
| Buprenorphine hydrochloride | 1 | 10 |
| Mycophenolate mofetil | 1 | 37 |
| Neostigmine methylsulfate and glycopyrrolate | 1 | 1 |
| Ganciclovir | 1 | 2 |
| Doxycycline | 1 | 63 |
| Leuprolide acetate | 1 | 16 |
| Bivalirudin | 1 | 13 |
| Calcitonin salmon | 1 | 13 |
| Trimethobenzamide hydrochloride | 1 | 7 |
| Posaconazole | 1 | 29 |
| Daptomycin | 1 | 25 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 39 | 62.9% |
| Injection, powder, lyophilized, for solution | 10 | 16.1% |
| Injection, solution | 8 | 12.9% |
| Solution | 2 | 3.2% |
| Injection, powder, for solution | 1 | 1.6% |
| Injection, solution, concentrate | 1 | 1.6% |
| Capsule | 1 | 1.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sugammadex sodium | 42023-935 | Solution | Generic drugs (ANDA) | July 28, 2026 |
| Sugammadex sodium | 42023-830 | Solution | Generic drugs (ANDA) | July 28, 2026 |
| Leuprolide acetate | 42023-259 | Injection | Generic drugs (ANDA) | June 30, 2026 |
| Daptomycin | 42023-295 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | October 27, 2025 |
| Adrenalin (epinephrine in sodium chloride) | 42023-500 | Injection | New drug applications (NDA) | May 19, 2025 |
| Adrenalin (epinephrine in sodium chloride) | 42023-721 | Injection | New drug applications (NDA) | May 14, 2025 |
| Adrenalin (epinephrine in sodium chloride) | 42023-434 | Injection | New drug applications (NDA) | May 14, 2025 |
| Adrenalin (epinephrine in sodium chloride) | 42023-273 | Injection | New drug applications (NDA) | May 14, 2025 |
| Doxycycline | 42023-244 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | November 26, 2024 |
| Naloxone Hydrochloride | 42023-224 | Injection | Generic drugs (ANDA) | November 5, 2024 |
| Adrenalin (epinephrine in sodium chloride) | 42023-315 | Injection | New drug applications (NDA) | October 4, 2024 |
| Pitocin | 42023-116 | Injection | New drug applications (NDA) | May 6, 2024 |
| Ephedrine sulfate | 42023-243 | Injection | New drug applications (NDA) | January 31, 2024 |
| Pitocin | 42023-116 | Injection | New drug applications (NDA) | December 22, 2023 |
| Bivalirudin | 42023-622 | Injection, solution | New drug applications (NDA) | June 19, 2023 |
| Prevduo | 42023-269 | Injection | New drug applications (NDA) | May 15, 2023 |
| Posaconazole | 42023-195 | Injection | Generic drugs (ANDA) | January 1, 2023 |
| Vasostrict | 42023-164 | Injection | New drug applications (NDA) | December 5, 2022 |
| Vasostrict | 42023-237 | Injection | New drug applications (NDA) | December 15, 2021 |
| Vasostrict | 42023-219 | Injection | New drug applications (NDA) | December 15, 2021 |
| Calcitonin Salmon | 42023-205 | Injection, solution | Generic drugs (ANDA) | November 10, 2021 |
| Ephedrine sulfate | 42023-243 | Injection | New drug applications (NDA) | January 31, 2021 |
| Dexmedetomidine Hydrochloride | 42023-187 | Injection, solution | Generic drugs (ANDA) | December 4, 2020 |
| Dexmedetomidine Hydrochloride | 42023-186 | Injection, solution | Generic drugs (ANDA) | December 4, 2020 |
| Adrenalin | 42023-168 | Injection | New drug applications (NDA) | December 4, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.